845729-40-0

Upstream product

• 845729-49-9 (2-chloroethoxy)-N-(2-methyl-4-nitrophenyl)acetamide 
• 109-11-5 morpholine-3-one 
• 455-88-9 5-nitro-2-fluorotoluene 
• 1427-07-2 2-fluoro-4-nitrotoluene 

Downstream Products

• 811811-33-3 EMD 495235 
• 811450-77-8 (2R)-2-(tert-butoxycarbonyl-amino)-3-methoxy-N-[3-methyl-4-(3-oxo-morpholin-4-yl)-phenyl]-propionamide 
• 811450-79-0 (2R)-2-amino-3-methoxy-N-[3-methyl-4-(3-oxo-morpholin-4-yl)-phenyl]-propionamide 

Relevant academic research and scientific papers

A Facile Oxidation of Tertiary Amines to Lactams by Using Sodium Chlorite: Process Improvement by Precise pH Adjustment with CO 2

By using cheap and innocuous sodium chlorite, a series of tertiary amines have been oxidized to the corresponding lactams with good selectivity and high yield. In this method, neither transition-metal catalyst nor oxidant was used. In the oxidation step, the pH of the sodium chlorite was precisely adjusted to pH around 6 using CO2, such pH is a compromise between oxidative properties, chemical stability, and unwanted precipitation. In addition, buffer salts are not necessary, which allows this oxidation reaction to be performed under safe and environmentally benign conditions.

SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS

The present invention relates to compounds of general formula (I) wherein A, B, L, R1, R2, R3a and R3b are defined as in the specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

Practical and efficient processes for the preparation of 4-(4-aminophenyl)morpholin-3-ones on a larger scale: Precursor of factor Xa inhibitors

Factor Xa inhibitors are interesting targets for the development of antithrombotic agents. Our personal efforts in the discovery of small molecule inhibitors led to the compounds EMD 495235 and EMD 503982, which entered preclinical and clinical studies, respectively. Therefore, kilograms of both drugs in particular 4-(4-aminophenyl)morpholin-3-one moieties have to be provided. The scale-up results of these special P-4 ligands will be described herein.

METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES

The invention relates to a method for production of compounds of formula (I), where X has the meaning given in claim 1 and precursors for the same.

Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa

Neutral chlorothiophenecarboxamides bearing an amino acid and a substituted aniline were synthesized and investigated for their factor Xa inhibitory activity in vitro. From selected 2-methylphenyl morpholinones the solution properties were determined. The most soluble and active compounds were then investigated in different animal species to compare the pharmacokinetic parameters. This led to a potent, water soluble and orally bioavailable candidate for further development: EMD 495235.